Johnson & Johnson Operating Expenses 2010-2022 | JNJ

Johnson & Johnson annual/quarterly operating expenses history and growth rate from 2010 to 2022. Operating expenses can be defined as the sum of all operating expenses for the given industry.
  • Johnson & Johnson operating expenses for the quarter ending March 31, 2022 were $17.564B, a 17.94% increase year-over-year.
  • Johnson & Johnson operating expenses for the twelve months ending March 31, 2022 were $73.671B, a 10.29% increase year-over-year.
  • Johnson & Johnson annual operating expenses for 2021 were $70.999B, a 7.43% increase from 2020.
  • Johnson & Johnson annual operating expenses for 2020 were $66.087B, a 2.09% increase from 2019.
  • Johnson & Johnson annual operating expenses for 2019 were $64.731B, a 1.81% increase from 2018.
Johnson & Johnson Annual Operating Expenses
(Millions of US $)
2021 $70,999
2020 $66,087
2019 $64,731
2018 $63,582
2017 $58,777
2016 $52,087
2015 $50,878
2014 $53,768
2013 $55,841
2012 $53,449
2011 $52,669
2010 $44,640
2009 $46,142
Johnson & Johnson Quarterly Operating Expenses
(Millions of US $)
2022-03-31 $17,564
2021-12-31 $19,968
2021-09-30 $19,489
2021-06-30 $16,650
2021-03-31 $14,892
2020-12-31 $20,828
2020-09-30 $16,681
2020-06-30 $14,396
2020-03-31 $14,182
2019-12-31 $16,529
2019-09-30 $19,082
2019-06-30 $13,521
2019-03-31 $15,599
2018-12-31 $17,272
2018-09-30 $15,925
2018-06-30 $15,857
2018-03-31 $14,528
2017-12-31 $17,635
2017-09-30 $14,860
2017-06-30 $14,091
2017-03-31 $12,191
2016-12-31 $13,782
2016-09-30 $12,539
2016-06-30 $13,578
2016-03-31 $12,188
2015-12-31 $14,053
2015-09-30 $12,980
2015-06-30 $12,046
2015-03-31 $11,799
2014-12-31 $15,551
2014-09-30 $11,657
2014-06-30 $13,869
2014-03-31 $12,691
2013-12-31 $15,605
2013-09-30 $13,908
2013-06-30 $13,084
2013-03-31 $13,244
2012-12-31 $14,458
2012-09-30 $13,457
2012-06-30 $14,440
2012-03-31 $11,094
2011-12-31 $15,937
2011-09-30 $11,894
2011-06-30 $13,175
2011-03-31 $11,663
2010-12-31 $13,416
2010-09-30 $10,763
2010-06-30 $11,110
2010-03-31 $9,351
2009-12-31 $13,947
2009-09-30 $10,836
2009-06-30 $10,976
2009-03-31 $10,383
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $467.100B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $308.070B 36.35
Pfizer (PFE) United States $294.179B 10.26
AbbVie (ABBV) United States $270.651B 11.86
Merck (MRK) United States $230.551B 13.02
Novartis AG (NVS) Switzerland $187.031B 13.61
GlaxoSmithKline (GSK) United Kingdom $110.644B 12.92
Novo Nordisk (NVO) Denmark $0.000B 33.16